Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00764270 · ClinicalTrials.gov registry record · Phase 2
The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease
A Phase 2 study, sponsored by Oregon State University.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00764270 is a Phase 2 study that has completed, run by Oregon State University. The registered enrollment target is 28 participants.
The verdict
NCT00764270, a Phase 2 study, has completed, sponsored by Oregon State University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a dietary supplement, R-alpha lipoic acid, is able to reduce risk factors in people with documented heart disease and increased levels of inflammation.
Interventions
- DIETARY_SUPPLEMENT R-alpha lipoic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-08-01 |
| Est. Completion | 2024-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00764270
The ClinicalTrials.gov registry entry for NCT00764270 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon State University, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which R-alpha lipoic acid is the first listed.
NCT00764270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00764270 about?
NCT00764270 is a clinical study titled "The Role of R-Alpha Lipoic Acid in the Treatment of Atherosclerotic Vascular Disease". The purpose of this study is to see if a dietary supplement, R-alpha lipoic acid, is able to reduce risk factors in people with documented heart disease and increased levels of inflammation.
What is the current status of trial NCT00764270?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2011-08-01. Estimated completion is 2024-10-01.
What interventions are being tested in trial NCT00764270?
The interventions under investigation include: R-alpha lipoic acid (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00764270?
This trial is sponsored by Oregon State University, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.